2026 Safety Guide
Alpha-Ketoglutarate (AKG) Side Effects
Complete Alpha-Ketoglutarate (AKG) safety profile: reported side effects from published research, contraindications, severity tiers, and how to minimize adverse reactions through proper dosing and vendor selection.
Reported Alpha-Ketoglutarate (AKG) side effects
What human studies recorded In a randomized crossover trial in hemodialysis patients in Copenhagen, 5 of 17 patients stopped calcium ketoglutarate within 1 to 2 weeks because of vomiting, anorexia, diarrhea or general uneasiness; all 5 had stomach or bowel symptoms before the study, and the other 12 reported no side effects (PMID: 9469496). Plasma ionized calcium was lower on calcium ketoglutarate than on calcium carbonate in that trial (PMID: 9469496). In a crossover trial in 28 hemodialysis patients, high blood calcium occurred in 1 patient on calcium ketoglutarate and 8 on calcium acetate (PMID: 10383011). In 20 patients after major abdominal surgery, tube feeding enriched with AKG lowered serum albumin more than standard feeding and did not improve nitrogen balance or clinical outcomes (PMID: 12297206). The longest human study found lasted 36 months, in 14 hemodialysis patients given calcium AKG as a phosphate binder, in whom serum phosphate and parathyroid hormone fell and serum calcium rose (PMID: 8676818). Animal data In the 2020 Buck Institute study, the authors did not detect significant adverse changes in mice fed 2 percent Ca-AKG from 18 months of age (PMID: 32877690). In the Interventions Testing Program's 2022 cohort, median lifespan with AKG differed from controls by +3.4 percent in males and -1.6 percent in females, neither statistically significant (PMID: 41843349). Gaps No human data on AKG supplements in pregnancy or breastfeeding were found, and no human pharmacokinetic or drug interaction studies of oral AKG supplements were found.
When to continue, reduce, or stop Alpha-Ketoglutarate (AKG)
Mild: continue protocol
Transient mild symptoms (slight GI upset, minor injection-site reaction, brief fatigue) typically resolve within 3-7 days as physiology adjusts. Continue at current dose; monitor weekly.
Moderate: reduce dose
Persistent mild symptoms past two weeks, or new symptoms like sustained mood changes, sleep disruption, or appetite shifts. Reduce dose by 25-50% and reassess at the end of the next 2-week window.
Severe: discontinue + seek care
Any signal of allergic response (rash, swelling, breathing difficulty), unexplained chest discomfort, severe injection-site reaction with infection signs, or vision changes. Discontinue immediately and consult a licensed practitioner.
Alpha-Ketoglutarate (AKG) contraindications
In a dialysis trial, the patients who could not tolerate calcium ketoglutarate all had gastrointestinal symptoms before starting (PMID: 9469496). In dialysis patients, calcium ketoglutarate lowered serum phosphate as other calcium phosphate binders do and changed blood calcium and amino acid levels (PMID: 10383011, PMID: 9469496, PMID: 8676801), so the salt is not metabolically neutral when the kidneys fail. No human data were found for pregnancy or breastfeeding.
Why vendor quality drives Alpha-Ketoglutarate (AKG) side-effect frequency
Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.
Full Alpha-Ketoglutarate (AKG) profile
Mechanism, dosing, half-life, peer-reviewed studies.
Alpha-Ketoglutarate (AKG) protocol
Three-tier dosing protocol with cycle structure.
Alternatives
If side-effect profile rules out Alpha-Ketoglutarate (AKG) for you, similar compounds.
Alpha-Ketoglutarate (AKG) side effects FAQ
What are the most common Alpha-Ketoglutarate (AKG) side effects?
What human studies recorded In a randomized crossover trial in hemodialysis patients in Copenhagen, 5 of 17 patients stopped calcium ketoglutarate within 1 to 2 weeks because of vomiting, anorexia, diarrhea or general uneasiness; all 5 had stomach or bowel symptoms before the study, and the other 12 reported no side effects (PMID: 9469496). Plasma ionized calcium was lower on calcium ketoglutarate
Are there severe side effects to watch for with Alpha-Ketoglutarate (AKG)?
Severe reactions are rare in published research but can occur. Watch for: allergic-type symptoms (rash, swelling, breathing difficulty), unexplained chest discomfort, infection signs at injection sites, vision changes, or severe persistent mood/sleep disruption. Any of these warrants immediate discontinuation and consultation with a licensed practitioner. The Severity Tiers section above triages mild → moderate → severe response patterns.
Does Alpha-Ketoglutarate (AKG) have contraindications?
In a dialysis trial, the patients who could not tolerate calcium ketoglutarate all had gastrointestinal symptoms before starting (PMID: 9469496). In dialysis patients, calcium ketoglutarate lowered serum phosphate as other calcium phosphate binders do and changed blood calcium and amino acid levels (PMID: 10383011, PMID: 9469496, PMID: 8676801), so the salt is not metabolically neutral when the ki
How can I minimize Alpha-Ketoglutarate (AKG) side effects?
Three biggest levers: (1) Start at the Beginner-tier dose for 2-3 weeks before escalating, which gives time to detect adverse signals at minimum effective dose. (2) Source from COA-verified vendors only: impurity profiles and mislabeled compounds drive a disproportionate share of reported side effects in research-compound communities. (3) Maintain adequate cycle off-time when applicable: receptor-saturating compounds benefit from 4-6 week breaks. The vendor section below lists the cheapest in-stock Alpha-Ketoglutarate (AKG) sources we track, each linked to its Trust Score (COA verification is 30% of the score).
Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.